ABOUT
- In recent years, tumor immunotherapy has become the core of cancer treatment research. With innovation as the driving force, Medicilon has vigorously developed a tumor immunity (Immuno-oncology) drug efficacy evaluation research platform. At present, CAR-T, TCR-T, CAR-NK, oncolytic virus, antibodies (monoclonal antibodies, bispecific antibodies, polyclonal antibodies, etc.), siRNA, AAV and other immunotherapy models and methods are used for evaluating the efficacy of immunotherapy and empowering the research process of innovative therapies and protect health!
Syngeneic Models- The homologous tumor transplantation model tests the ability of model animals to use their perfect immune system to fight cancer and the therapeutic effect of immunotherapy.The choices we offer you are:
Cancer Type Cell Lines Breast Cancer 4T1, EMT6, JC, C1271 Lung Cancer LLC1(LLC1-luc), KLN205 Colon Cancer CT26.WT, MC-38, CMT-93 Pancreatic Cancer Panc 02 Renal Cancer RENCA Melanoma B16-F10(B16-F10-luc), Clone-M3 Liver Cancer H22, Hepa 1-6 Lymphoma A20, EL4, P388D1, L5178-R, E.G7-OVA Leukemia C1498, L1210, WEHI-3 Myeloma J558 Mastocytoma P815 
Flow cytometric typing of immune cells in model blood
Syngenic Models for detecting pharmacological effects of PD-1 drugs
PBMC Humanized Models- The humanized tumor mouse model of partially reorganized human immune system is particularly effective for short-term research or high-throughput research.The types of models currently available for Medicilon are:
Cancer Type Cell Lines Cancer Type Cell Lines Breast Cancer HCC1954 Lymphoma Raji, MOLM-13 Colon Cancer HT29, Lovo, Ls174T Myeloma NCI-H929 Lung Cancer NCI-H292, HCC827 Skin Cancer A431 Leukemia (AML) THP-1 Ovarian Cancer OVCAR-3 
Tumor growth and drug efficacy evaluation of PBMC humanized mouse lymphoma transplantation model
CD34+ HSC Humanized Models- Humanized mice transplanted with CD34+ human umbilical cord blood cells to reconstruct the human hematopoietic system are colonized in the mouse bone marrow, and continuously and stably produce various human hematopoietic cells and immune cells, and use the human immune system to evaluate various immunotherapy.Medicilon’s currently available models are:
Cancer Type Cell Lines Brain Cancer U-87 MG Breast Cancer HCC1954, MDA-MB-231, JIMT-1 Colon Cancer HT29, LoVo Gastric Cancer NCI-N87 Lung Cancer HCC827, NCI-H1975, NCI-H292, A549 Lymphoma Raji, TMD8, MOLM-13 Myeloma RPMI-8226, NCI-H929 Pancreatic Cancer Capan-2 Skin Cancer A431 Urinary Bladder Cancer UM-UC-3 
Model Mice Produce Human-Derived Hematopoietic stem cells and Immune Cells
& Tumorigenesis of breast cancer cells in hematopoietic stem cell humanized mice
Orthotopic Model- The xenogeneic orthotopic tumor transplantation model can fully consider the interaction of tumor cells and the organ microenvironment between the surrounding stroma and monitor tumor growth when evaluating drug efficacy.
Cancer Type Orthotopic Model Orthotopic Model (Luc Cell Line) Brain Cancer U87-MG U87-MG-luc Lung cancer NCI-H1650, A549, NCI-H1975, NCI-H460, LLC1 A549-luc,LLC1-luc, NCI-H1975-luc Colon cancer HCT-116, LoVo HT29-luc Gastric cancer Hs 746T Pancreas cancer Mia-Paca 2 Mia-Paca ;2-luc Breast cancer MDA-MB-231 4T1-luc Ovarian cancer SK-OV-3 SK-OV-3-luc Prostate Cancer PC3 PC-3-luc Renal Cancer A498 Bladder Cancer UM-UC-3 Melanoma B16-F10-luc Liver Cancer H22 Bone Cancer Medicilon will break the barriers of experimentation and technology for you. At present, it has mature orthotopic transplantation technology, including orthotopic brain transplantation, orthotopic liver transplantation, orthotopic lung transplantation, orthotopic transplantation of tibia marrow cavity, orthotopic intravesical transplantation Transplant etc.Orthotopic brain transplantation
Lung metastasis model
Tibia bone marrow cavity orthotopic transplantation
Orthotopic ovarian cancer transplantation
PDX Models- The human tumor transplantation model PDX retains the characteristics of the patient’s tumor tissue and is more clinically relevant. Combined with humanized mice, it can establish an ideal tumor immunotherapy evaluation model.Medicilon has now developed:
Cancer Type Cell Lines Colon Cancer PDXM-008C, PDXM-016C, PDXM-020C, PDXM-021C, PDXM-057C, PDXM-060C, PDXM-075C, PDXM-076C, PDXM-087C, PDXM-104C, PDXM-095C, PDXM-084C, PDXM-072C, PDXM-069C, PDXM-057C, PDXM-015C, PDXM-002C, Lung Cancer PDXM-054Lu, PDXM-050Lu, PDXM-047Lu, PDXM-053Lu, PDXM-028Lu, Gastric Cancer PDXM-092Ga, PDXM-091Ga, Breast Cancer PDXM-201B, PDXM-202B, PDX-203B Liver Cancer PDXM-211Li, PDXM-212Li Pancreas Cancer PDXM-221Pa, PDXM-222Pa Bladder Cancer PDXM-231U, PDXM-232U Lymphoma PDXM-241Ly, PDXM-242Ly Medicilon’s PDX model research includes molecular level genotyping and tumor model pharmacological efficacy evaluation services, providing a highly predictive model for the study of clinical efficacy.
TMB gene mutation load detection and model tumor growth curve in PDX model of lung cancer
